Geneos Wealth Management’s Invesco FTSE RAFI Emerging Markets ETF PXH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.14K Hold
177
– – ﹤0.01% 2631
2026
Q2
$4.94K Buy
+177
New +$5.05K ﹤0.01% 2190
2025
Q2
– Sell
-1,719
Closed -$37.4K – 3195
2025
Q1
$37.4K Buy
+1,719
New +$36.8K ﹤0.01% 1645
2024
Q1
– Sell
-3,347
Closed -$63.9K – 2202
2023
Q4
$63.9K Sell
3,347
-1,481
-31% -$26.8K ﹤0.01% 986
2023
Q3
$86K Hold
4,828
– – ﹤0.01% 912
2023
Q2
$90K Hold
4,828
– – ﹤0.01% 905
2023
Q1
$88.6K Buy
+4,828
New +$89.2K 0.01% 880
2022
Q3
– Sell
-72
Closed -$1K – 2461
2022
Q2
$1K Buy
+72
New +$1.4K ﹤0.01% 2530
2018
Q4
– Sell
-500
Closed -$10K – 2464
2018
Q3
$10K Sell
500
-855
-63% -$18K ﹤0.01% 1845
2018
Q2
$28K Buy
+1,355
New +$30.1K ﹤0.01% 1314

Other funds holding PXH

Geneos Wealth Management's PXH Position: Q3 2026 in Review

Geneos Wealth Management held its Invesco FTSE RAFI Emerging Markets ETF (PXH) position steady in Q3 2026 at 177 shares worth $5.14K. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

Geneos Wealth Management first reported a position in PXH in Q2 2018 and has held it in 10 quarters since. The position peaked at $90K in Q2 2023. 243 funds tracked by Wall St. Rank hold PXH as of Q3 2026.

  • Geneos Wealth Management held 177 shares of Invesco FTSE RAFI Emerging Markets ETF worth $5.14K as of Q3 2026.
  • Geneos Wealth Management left its Invesco FTSE RAFI Emerging Markets ETF share count unchanged in Q3 2026.
  • Invesco FTSE RAFI Emerging Markets ETF made up ﹤0.01% of Geneos Wealth Management's portfolio in Q3 2026, its #2631 holding.
  • Geneos Wealth Management first reported a position in Invesco FTSE RAFI Emerging Markets ETF in Q2 2018 and has held it in 10 quarters since.
  • Geneos Wealth Management's Invesco FTSE RAFI Emerging Markets ETF position peaked at $90K in Q2 2023.
  • 243 funds tracked by Wall St. Rank held Invesco FTSE RAFI Emerging Markets ETF as of Q3 2026.

Based on Geneos Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.